Dermatoscopy to Account for the Most Prominent Share in the Melanoma Therapeutics Market, Owing to Its Applicability in the Diagnosis of All Melanoma Types

Tue, 07 May 2019 7:07

Melanoma is highly prevalent in North America and Europe as it predominantly affects fair skin that freckles and burns easily. The primary cause of melanoma is ultraviolet radiation (UV) exposure. Increasing air pollution levels with rising exposure to UV rays are collectively leading to an increase in the number of melanoma incidences around the globe.

Market Segmentation

The global melanoma therapeutics market can be segmented by cancer type, diagnosis, treatment, and region.

By cancer type, the market can be segmented into superficial spreading melanoma, nodular melanoma, lentigno maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, and others. Superficial spreading melanoma has the highest prevalence at approximately 51%, followed by lentigno maligna melanoma, which has around 37% prevalence around the globe.

By diagnosis, the melanoma therapeutics market can be segmented into dermatoscopy, entinel lymph node biopsy, blood test, X-ray, ultrasound, and CT scan. Among these, the dermatoscopy segment is projected to account for a sizable market share, due to the applicability of dermatoscopy in the diagnosis of all types of melanoma. 

By treatment, the market can be segmented into chemotherapy, biological therapy, radiotherapy, targeted therapy, and immune therapy. The chemotherapy segment is expected to account for a prominent market share on account of the broad range of therapeutics containing protein and others. The immune therapy segment is estimated to register the highest CAGR during the forecast period, 2019–2026. Increasing prevalence of advanced melanoma with growing innovation in genomics is accelerating demand for immune cancer therapies in melanoma treatment.

Regional Analysis

By region, the melanoma therapeutics market has been segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East and Africa.

North America is projected to dominate the melanoma therapeutics market, owing to the increasing prevalence of melanoma in countries across the region. Highly-advanced healthcare infrastructure and a large number of developed healthcare facilities in North America are the key factors driving the growth of the melanoma therapeutics market.

Europe is the second largest melanoma therapeutics market globally, followed by Asia Pacific, owing to the region’s large patient pool suffering from melanoma and high healthcare expenditure.

Asia Pacific is expected to observe significant growth in the global melanoma therapeutics market on account of the increasing incidences of skin cancer, due to UV exposure. Increasing air pollution levels in the region are affecting UV exposure and leading to an increase in the prevalence of skin disease. Though, it should be noted that the region has low incidences of malignant melanoma.

The LAMEA region is anticipated to sluggish growth, owing to the region’s poor healthcare infrastructure. Further, the region has a low prevalence rate of melanoma.

Key Players

Some of the key market players in the melanoma therapeutics market are Abbott Diagnostics, Agilent Technologies, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Qiagen N.V. Company, Roche, and Sanofi, among others.